PHIA Koninklijke Philips N.V.

Mercurius Health equips Robert Janker Klinik with integrated oncology solutions from Philips and Elekta

Mercurius Health equips Robert Janker Klinik with integrated oncology solutions from Philips and Elekta

May 10, 2023 

The hospital will be equipped with state-of-the-art diagnostic and therapeutic oncology solutions over the next three years, contributing to enhanced patient care

Amsterdam, the Netherlands, Stockholm, Sweden, and Madrid, Spain – (NYSE: PHG, AEX: PHIA), a global leader in health technology, radiation therapy leader (EKTA-B.ST), and oncology service provider today announced the signing of a 3-year agreement under which Philips and Elekta will install state-of-the-art diagnostic and therapeutic oncology equipment and associated informatics solutions at Mercurius Health’s newly-acquired cancer center in Bonn, Germany. The investment in Philips and Elekta solutions by Mercurius Health is part of its commitment to establishing a major presence in Germany, following the company’s acquisition of Robert Janker Klinik earlier this year.  

The agreement has been enabled by the between Philips and Elekta to advance comprehensive personalized cancer care through the deployment of precision oncology solutions. The Robert Janker Klinik, a specialized hospital in oncology and palliative care, focuses on minimally invasive diagnostics and treatments for cancer. The hospital has three inpatient departments (radiology, radiotherapy and palliative care) and an outpatient unit for radiotherapy. It employs around 130 staff and treats patients from across the region as well as national and international patients.

“This major investment in cutting-edge technology by Mercurius Health means many of the projects currently in planning can be rapidly moved forward, making us a showcase for what the future of cancer care will look like,” said Prof. Dr. Attila Kovács, Head Physician of the Clinic for Diagnostic and Interventional Radiology and Neuroradiology.

“The combination of Philips’ diagnostic imaging and oncology informatics solutions, and Elekta’s radiation therapy solutions means we will be able to offer our patients state-of-the-art therapy for tumors such as prostate and liver cancer that are currently difficult to treat, improving clinical outcomes,” said Prof. Dr. Michael Pinkawa, Radiation Oncologist and Head of Radiotherapy at Robert Janker Klinik.

Bringing data and actionable insights to the benefit of cancer patients

To make a precise and informed diagnosis and select the optimal therapy for each individual cancer patient, oncologists often need to consider and scrutinize around 10,000 data points, many of which reside in disparate IT systems – electronic medical records, lab systems, radiology, pathology, and genomics. Philips and Elekta bring all this data together and translate it into actionable insights, and pathways with predictable outcomes for each patient [1].

The combined solutions enable oncologists to deliver precise and personalized therapies that treat tumors effectively while sparing adjacent tissue and organs at risk. Installed in Robert Janker Klinik, they will provide Mercurius Health with a platform to showcase its consultancy and B2B oncology services in the German market and continue its pioneering work in increasing productivity, improving patient and staff experience, and enhancing clinical care.

[1] Results from case studies are not predictive of results in other cases. Results in other cases may vary.

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

E-mail:

Mattias Thorsson

Vice President, Head of Corporate Communications, Elekta

Tel:

E-mail: 

Laura Terzagui Fernández

Director of Marketing & Communications, Mercurius Health

Tel:

E-mail: 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit or follow @Elekta on Twitter.

About Mercurius Health

Mercurius Health is the European leader of B2B services to hospitals and oncology centers with specializations in radiotherapy, nuclear medicine and radiology. Services include advisory, remote planning, commissioning, training & education, outsourced operations and financing of equipment used in centers and are mostly provided in Europe and Africa.



 

Attachment



EN
10/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for spe...

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real timeWith the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging a...

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch